What SEC filings does Bicycle Therapeutics plc submit to the SEC?

Bicycle Therapeutics plc (BCYC) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about BCYC?

A Form 4 for BCYC discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Bicycle Therapeutics plc?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for BCYC?

The 10-K is Bicycle Therapeutics plc's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all BCYC SEC filings directly on EDGAR?

You can view all historical Bicycle Therapeutics plc filings on the SEC EDGAR company page for BCYC. Each filing card on this page links directly to the original SEC document.

How often does Bicycle Therapeutics plc file with the SEC?

Bicycle Therapeutics plc files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling BCYC shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

BCYC SEC Filing News — Bicycle Therapeutics plc

Latest SEC filings for Bicycle Therapeutics plc (BCYC) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-06.

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expr…

Sector: Healthcare Industry: Biotechnology Market Cap: $242.2M CIK: 1761612

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for BCYC currently lean bearish. Of the 20 filing records displayed, 11 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

BCYC Filing Activity Snapshot 2026-07-02 — 2026-10-06

Insider Transactions (Form 4)

0 buys vs 11 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$34.2K

Lee Kevin · 2026-07-02

8,000 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 15 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 15 filings in this group are Form 4s for Bicycle Therapeutics plc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 15 insider filings shown, the breakdown is 11 open-market sale and 4 compensation award. 11 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×11: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×4: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Open-market sale Insider Selling 2026-10-06

BCYC insider Swanton Robert Charles (Director) sold 3,431 shares (~$11.9K)

Swanton Robert Charles, listed as Director at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 3,431 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	3,431	$3.47	$11.9K

Filing: Form 4 (Insider Transaction) Insider: Swanton Robert Charles (Director) Shares: 3,431 Est. Value: $11.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-06

BCYC insider Skynner Michael (CHIEF SCIENTIFIC OFFICER) sold 2,445 shares (~$8.5K)

Skynner Michael, listed as CHIEF SCIENTIFIC OFFICER at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 2,445 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,942	$3.47	$6.7K
`S`	Open-market sale	503	$3.57	$1.8K

Filing: Form 4 (Insider Transaction) Insider: Skynner Michael (CHIEF SCIENTIFIC OFFICER) Shares: 2,445 Est. Value: $8.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-06

BCYC insider Hannay Michael Charles Ferguson (CHIEF PROD & SUPPLY CHAIN OFF) sold 1,814 shares (~$6.3K)

Hannay Michael Charles Ferguson, listed as CHIEF PROD & SUPPLY CHAIN OFF at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 1,814 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,572	$3.47	$5.5K
`S`	Open-market sale	242	$3.57	$863.94

Filing: Form 4 (Insider Transaction) Insider: Hannay Michael Charles Ferguson (CHIEF PROD & SUPPLY CHAIN OFF) Shares: 1,814 Est. Value: $6.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-06

BCYC insider Perry Jennifer Scott (Chief Operating Officer) sold 1,500 shares (~$5.3K)

Perry Jennifer Scott, listed as Chief Operating Officer at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 1,500 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,094	$3.47	$3.8K
`S`	Open-market sale	80	$3.56	$284.80
`S`	Open-market sale	326	$3.78	$1.2K

Filing: Form 4 (Insider Transaction) Insider: Perry Jennifer Scott (Chief Operating Officer) Shares: 1,500 Est. Value: $5.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-06

BCYC insider Lee Kevin (Director, CHIEF EXECUTIVE OFFICER) sold 7,805 shares (~$27.2K)

Lee Kevin, listed as Director, CHIEF EXECUTIVE OFFICER at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 7,805 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	6,167	$3.47	$21.4K
`S`	Open-market sale	1,638	$3.57	$5.8K

Filing: Form 4 (Insider Transaction) Insider: Lee Kevin (Director, CHIEF EXECUTIVE OFFICER) Shares: 7,805 Est. Value: $27.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-06

BCYC insider Thompson Travis Alvin (Chief Financial Officer) sold 972 shares (~$3.4K)

Thompson Travis Alvin, listed as Chief Financial Officer at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 972 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	893	$3.47	$3.1K
`S`	Open-market sale	79	$3.57	$282.03

Filing: Form 4 (Insider Transaction) Insider: Thompson Travis Alvin (Chief Financial Officer) Shares: 972 Est. Value: $3.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

BCYC insider Form 4 filed for equity award, exercise, or tax withholding

Thompson Travis Alvin (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	60,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Thompson Travis Alvin (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

BCYC insider Form 4 filed for equity award, exercise, or tax withholding

Hannay Michael Charles Ferguson (CHIEF PROD & SUPPLY CHAIN OFF) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	60,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Hannay Michael Charles Ferguson (CHIEF PROD & SUPPLY CHAIN OFF)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

BCYC insider Form 4 filed for equity award, exercise, or tax withholding

Skynner Michael (CHIEF SCIENTIFIC OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	60,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Skynner Michael (CHIEF SCIENTIFIC OFFICER)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

BCYC insider Form 4 filed for equity award, exercise, or tax withholding

Perry Jennifer Scott (Chief Operating Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	60,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Perry Jennifer Scott (Chief Operating Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-07

BCYC insider Perry Jennifer Scott (Chief Operating Officer) sold 1,412 shares (~$6.1K)

Perry Jennifer Scott, listed as Chief Operating Officer at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 1,412 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,036	$4.27	$4.4K
`S`	Open-market sale	43	$4.31	$185.33
`S`	Open-market sale	333	$4.34	$1.4K

Filing: Form 4 (Insider Transaction) Insider: Perry Jennifer Scott (Chief Operating Officer) Shares: 1,412 Est. Value: $6.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-07

BCYC insider Skynner Michael (CHIEF SCIENTIFIC OFFICER) sold 2,391 shares (~$10.2K)

Skynner Michael, listed as CHIEF SCIENTIFIC OFFICER at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 2,391 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,859	$4.27	$7.9K
`S`	Open-market sale	532	$4.31	$2.3K

Filing: Form 4 (Insider Transaction) Insider: Skynner Michael (CHIEF SCIENTIFIC OFFICER) Shares: 2,391 Est. Value: $10.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-07

BCYC insider Lee Kevin (Director, CHIEF EXECUTIVE OFFICER) sold 7,642 shares (~$32.7K)

Lee Kevin, listed as Director, CHIEF EXECUTIVE OFFICER at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 7,642 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	5,905	$4.27	$25.2K
`S`	Open-market sale	1,737	$4.31	$7.5K

Filing: Form 4 (Insider Transaction) Insider: Lee Kevin (Director, CHIEF EXECUTIVE OFFICER) Shares: 7,642 Est. Value: $32.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-07

BCYC insider Hannay Michael Charles Ferguson (CHIEF PROD & SUPPLY CHAIN OFF) sold 1,761 shares (~$7.5K)

Hannay Michael Charles Ferguson, listed as CHIEF PROD & SUPPLY CHAIN OFF at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 1,761 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,506	$4.27	$6.4K
`S`	Open-market sale	255	$4.31	$1.1K

Filing: Form 4 (Insider Transaction) Insider: Hannay Michael Charles Ferguson (CHIEF PROD & SUPPLY CHAIN OFF) Shares: 1,761 Est. Value: $7.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-07

BCYC insider Thompson Travis Alvin (Chief Financial Officer) sold 923 shares (~$3.9K)

Thompson Travis Alvin, listed as Chief Financial Officer at BICYCLE THERAPEUTICS PLC, reported an open-market sale of 923 BCYC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	819	$4.27	$3.5K
`S`	Open-market sale	104	$4.31	$448.24

Filing: Form 4 (Insider Transaction) Insider: Thompson Travis Alvin (Chief Financial Officer) Shares: 923 Est. Value: $3.9K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Bicycle Therapeutics plc has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-02

BCYC Form 144 filed for proposed insider sale by Lee Kevin (9,000 shares) ~$31.2K

Lee Kevin filed a Form 144 with the SEC indicating intent to sell BCYC (BICYCLE THERAPEUTICS PLC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Lee Kevin Shares: 9,000 Est. Value: $31.2K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-02

BCYC Form 144 filed for proposed insider sale by Lee Kevin (8,000 shares) ~$34.2K

Filing: Form 144 (Proposed Sale Notice) Insider: Lee Kevin Shares: 8,000 Est. Value: $34.2K

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Bicycle Therapeutics plc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-20

BCYC filed 8-K — material company event

BICYCLE THERAPEUTICS PLC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-30

BCYC filed 8-K — material company event

BICYCLE THERAPEUTICS PLC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Bicycle Therapeutics plc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-30

BCYC filed Quarterly Report (10-Q)

BICYCLE THERAPEUTICS PLC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Bicycle Therapeutics plc's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on BCYC. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — BCYC SEC Filings

More Tools for BCYC

BCYC Full Stock Analysis BCYC Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper BCYC analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the BCYC stock analysis page.

BCYC Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer